Počet záznamů: 1  

Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor

  1. 1.
    SYSNO ASEP0343928
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevAntiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor
    Tvůrce(i) Kryštof, Vladimír (UEB-Q) RID, ORCID
    McNae, I. W. (GB)
    Walkinshaw, M. D. (GB)
    Fischer, P.M. (GB)
    Müller, P. (CZ)
    Vojtešek, B. (CZ)
    Orság, Martin (UEB-Q)
    Havlíček, Libor (UEB-Q) RID, ORCID
    Strnad, Miroslav (UEB-Q) RID, ORCID
    Zdroj.dok.Cellular and Molecular Life Sciences - ISSN 1420-682X
    Roč. 62, č. 15 (2005), s. 1763-1771
    Poč.str.9 s.
    Jazyk dok.eng - angličtina
    Země vyd.CH - Švýcarsko
    Klíč. slovaolomoucine II ; roscovitine ; cyclin-dependent kinase inhibitor
    Vědní obor RIVCE - Biochemie
    CEPGP204/03/D231 GA ČR - Grantová agentura ČR
    CEZAV0Z50380511 - UEB-Q (2005-2011)
    UT WOS000232497200011
    DOI10.1007/s00018-005-5185-1
    AnotaceThe study describes the protein kinase selectivity profile, as well as the binding mode of olomoucine II in the catalytic cleft of CDK2, as determined from co-crystal analysis. Apart from the main cell cycle-regulating kinase CDK2, olomoucine II exerts specificity for CDK7 and CDK9, with important functions in the regulation of RNA transcription. In vitro anticancer activity of the inhibitor in a panel of tumor cell lines shows a wide potency range with a slight preference for cells harboring a wild-type p53 gene. Cell-based assays confirmed activation of p53 protein levels and events leading to accumulation of p21(WAF1). Additionally, in olomoucine II-treated cells, Mdm2 was found to form a complex with the ribosomal protein L11, which inhibits Mdm2 ubiquitin ligase function. We conclude that perturbations in RNA synthesis may lead to activation of p53 and that this contributes to the antiproliferative potency of cyclin-dependent kinase inhibitors.
    PracovištěÚstav experimentální botaniky
    KontaktDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Rok sběru2011
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.